AI Article Synopsis
- Researchers are exploring new ways to deliver oligonucleotides like siRNA and ASOs specifically to CD22-expressing B cells, which could enhance their effectiveness as medicines.* -
- Current methods for targeting these cells include antibodies and nanoparticles, but this is the first report of successfully delivering siRNA specifically to CD22-targeted cells.* -
- The study demonstrates that using a modified glycan ligand attached to siRNA can improve gene expression knockdown in B cells, potentially leading to new treatments for conditions like B cell lymphomas.*
Article Abstract
Extrahepatic targeted delivery of oligonucleotides, such as small interfering RNA (siRNA) and antisense oligonucleotides (ASOs), is an attractive technology for the development of nucleic acid-based medicines. To target CD22-expressing B cells, several drug platforms have shown promise, including antibodies, antibody-drug conjugates, and nanoparticles, but to date CD22-targeted delivery of oligonucleotide therapeutics has not been reported. Here we report the uptake and enhancement of siRNA gene expression knockdown in CD22-expressing B cells using a chemically stabilized and modified CD22 glycan ligand-conjugated siRNA. This finding has the potential to broaden the use of siRNA technology, opening up novel therapeutic opportunities, and presents an innovative approach for targeted delivery of siRNAs to B cell lymphomas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acschembio.1c00652 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inotuzumab Ozogamicin: First Pediatric Approval.
Paediatr Drugs
July 2024
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Inotuzumab ozogamicin (BESPONSA™) is a CD22-targeted monoclonal antibody drug conjugate (ADC) developed by Pfizer for the treatment of CD22-postive B-cell precursor acute lymphoblastic leukaemia (ALL). Inotuzumab ozogamicin comprises a humanized IgG4 anti-CD22 monoclonal antibody covalently linked to the potent DNA-binding cytotoxic agent N-acetyl-gamma-calicheamicin dimethylhydrazide (CalichDMH) via a linker. Inotuzumab ozogamicin binds to CD22-expressing tumour cells, facilitating the delivery of conjugated CalichDMH, which after intracellular activation induces double strand DNA breaks, ultimately leading to cell cycle arrest and apoptotic cell death.
View Article and Find Full Text PDFHigh yield killing of lymphoma cells by anti-CD22 CAR-NK cell therapy.
In Vitro Cell Dev Biol Anim
April 2024
Hematology and Cell Therapy Department, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Chimeric antigen receptors (CARs) offer a promising new approach for targeting B cell malignancies through the immune system. Despite the proven effectiveness of CAR T cells targeting CD19 and CD22 in hematological malignancies, it is imperative to note that their production remains a highly complex process. Unlike T cells, NK cells eliminate targets in a non-antigen-specific manner while avoiding graft vs.
View Article and Find Full Text PDFGenomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Blood
July 2024
Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Article Synopsis
- * The study found that 11% of patients who relapsed after InO developed mutations in the CD22 gene, which allowed cancer cells to evade treatment, often through losing or altering the CD22 protein's structure.
- * Additional mutations were also seen in genes related to DNA damage response, raising concerns about how cancer cells adapt post-treatment, emphasizing the need for understanding these mechanisms to improve future therapies, especially before procedures like stem cell transplantation.
Article Synopsis
- Inotuzumab ozogamicin (InO) is a targeted therapy for B-cell acute lymphoblastic leukemia that delivers a cytotoxic drug to cells expressing the CD22 antigen.
- A study on patients treated with InO revealed that approximately 11% exhibited genomic mutations contributing to treatment resistance, with various escape mechanisms like protein truncation and destabilization.
- The findings highlight the role of DNA damage repair processes in promoting CD22 mutations and suggest that understanding these genetic changes can help improve treatment strategies for overcoming resistance to therapy.
CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.
Blood
January 2024
Department of Bone Marrow Transplantation, Great Ormond Street Children's Hospital, London, United Kingdom.
CD19-negative relapse is a leading cause of treatment failure after chimeric antigen receptor (CAR) T-cell therapy for acute lymphoblastic leukemia. We investigated a CAR T-cell product targeting CD19 and CD22 generated by lentiviral cotransduction with vectors encoding our previously described fast-off rate CD19 CAR (AUTO1) combined with a novel CD22 CAR capable of effective signaling at low antigen density. Twelve patients with advanced B-cell acute lymphoblastic leukemia were treated (CARPALL [Immunotherapy with CD19/22 CAR Redirected T Cells for High Risk/Relapsed Paediatric CD19+ and/or CD22+ Acute Lymphoblastic Leukaemia] study, NCT02443831), a third of whom had failed prior licensed CAR therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!